Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines
- PMID: 7384789
- DOI: 10.1126/science.7384789
Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines
Abstract
Mice of two different strains were injected subcutaneously with spontaneously metastasizing syngeneic melanomas. After 4 to 6 weeks, the local tumors were removed and, 3 days after surgery, treatment of the metastases was initiated. The treatment consisted of intravenous injections of liposomes containing lymphokines or control supernatant fluids. Liposomes were injected twice weekly for 3 weeks, and the mice were killed 2 weeks later. Seventy-three percent of the mice injected with liposomes containing lymphokines were free of metastases, whereas only 10 percent of the mice treated with control liposomes were tumor-free. These experiments suggest that this form of therapy may provide a valuable addition to the more conventional approaches to the eradication of cancer metastases.
Similar articles
-
Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyl dipeptide.Proc Natl Acad Sci U S A. 1981 Mar;78(3):1680-4. doi: 10.1073/pnas.78.3.1680. Proc Natl Acad Sci U S A. 1981. PMID: 6940181 Free PMC article.
-
Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators.Cancer Res. 1982 Feb;42(2):496-501. Cancer Res. 1982. PMID: 7055801
-
Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.J Immunol. 1984 Jul;133(1):515-8. J Immunol. 1984. PMID: 6373933
-
Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide.J Natl Cancer Inst. 1982 Nov;69(5):1198-98. J Natl Cancer Inst. 1982. PMID: 6957661
-
The generation of tumoricidal activity in macrophages for the treatment of established metastases.Symp Fundam Cancer Res. 1983;36:421-35. Symp Fundam Cancer Res. 1983. PMID: 6382518 Review. No abstract available.
Cited by
-
Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine.Cancer Immunol Immunother. 1986;21(3):169-73. doi: 10.1007/BF00199357. Cancer Immunol Immunother. 1986. PMID: 3698058 Free PMC article.
-
Recruitment of exogenous macrophages into metastases at different stages of tumor growth.Cancer Immunol Immunother. 1987;24(2):93-8. doi: 10.1007/BF00205584. Cancer Immunol Immunother. 1987. PMID: 3829054 Free PMC article.
-
Expression of the metastatic phenotype in cells transfected with human metastatic tumor DNA.Proc Natl Acad Sci U S A. 1985 Mar;82(6):1726-30. doi: 10.1073/pnas.82.6.1726. Proc Natl Acad Sci U S A. 1985. PMID: 3856854 Free PMC article.
-
Macrophages in cancer metastases and their relevance to metastatic growth.Cancer Metastasis Rev. 1983;2(1):75-88. doi: 10.1007/BF00046906. Cancer Metastasis Rev. 1983. PMID: 6352008 Review.
-
Combination therapy with a synthetic peptide of C-reactive protein and interleukin 2: augmented survival and eradication of pulmonary metastases.Cancer Immunol Immunother. 1994 Jan;38(1):38-42. doi: 10.1007/BF01517168. Cancer Immunol Immunother. 1994. PMID: 8299117 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical